Fig 1.
PRISMA flow diagram of captured publications.
*Other reasons for exclusion at full-text screening stage were small population size (<20 SCLC patients) or duplicating results that had already been captured. **“Other” grey literature items were sourced through internet searches. HRQoL = health-related quality of life; n = number of records; PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-Analyses.
Table 1.
Number of publications reporting each outcome in the SCLC population, per line of therapy.
Fig 2.
Median OS (months) at first line[28, 30, 34, 35, 37, 38, 44, 51].
*One patient received radiotherapy only. **Three patients received radiotherapy only. CT = chemotherapy; ERCC1- = excision repair cross-complementation group 1 negative; ERCC1+ = excision repair cross-complementation group 1 gene positive; n = number of patients; NA = not available; OS = overall survival; PCI = prophylactic cranial irradiation; pts = patients; TRT = thoracic radiotherapy.
Fig 3.
Most common TRAEs reported for patients treated with SCLC therapies[30, 35, 42, 51].
Note: Presented TRAEs exceed 5% or lead to discontinuation. *These TRAEs were specified as grade 3–4. **These outcomes refer to febrile neutropenia specifically. CT = chemotherapy; n = number of patients; pts = patients; SCLC = small-cell lung cancer; TRAEs = treatment-related adverse events; TRT = thoracic radiotherapy.
Fig 4.
Median OS (months) at second line[36, 43, 62, 68].
CM = cranial metastasis; CT = chemotherapy; n = number of patients; OS = overall survival; pts = patients.
Fig 5.
Median OS (months) at third line[15, 49, 52, 60, 63].
2L = second line; CAV = cyclophosphamide, doxorubicin and vincristine; CR = complete response; CT = chemotherapy; n = number of patients; OS = overall survival; PD = progressive disease; PR = partial response; pts = patients; SD = stable disease.